Driven By Purpose
Patients with psychiatric and neurological disorders deserve better treatments. At Xylo, we are developing innovative, mechanism-based therapies to provide effective solutions for these complex conditions. By redefining care, we aim to address critical unmet needs and create lasting impact for patients and healthcare systems.
Our Story
Xylo Bio is a clinical-stage biotechnology company advancing the next generation of neurotherapeutics to address significant unmet medical needs worldwide.
The company has built a pipeline of novel, non-hallucinogenic neuroplastogens engineered for oral delivery and scalable clinical utility.
The company’s compounds, developed with cutting-edge computational drug discovery, have demonstrated receptor selectivity, and promote neuroplasticity relevant to neuropsychiatric conditions while avoiding mechanisms linked to effects of psychedelics that restrict patient access.
Investors
.webp)